Skip to main
ACIU

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune is well-positioned for success with its focus on Precision Medicine and therapeutic and diagnostic products targeting misfolded proteins for neurodegenerative diseases, supported by additional partnerships and a robust pipeline. The company's potential revenue streams, including from its programmed cell death therapeutics, are further bolstered by its competitive advantages in active immunotherapy and its versatile Morphomer platform. While there are technical risks, AC Immune's strong platform, impressive pipeline, and timely offerings make for a positive outlook for the future of the company.

Bears say

AC Immune is likely to experience delays in decisions from partner Takeda due to enrollment in the ACI24 Cohort AD4 of the ABATE trial and the lack of obvious clinical effects for their drug that modifies the course of PD. Additionally, while there have been positive results in terms of reduced levels of protein aggregates, the ultimate impact on motor and cognitive function still needs to be quantified and the ideal target product profile remains uncertain. Overall, AC Immune may struggle to show significant success in their clinical trials and may face challenges with delayed decision-making and uncertainty about their drug's effectiveness.

AC Immune (ACIU) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 1 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.